A5051311291- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Acute Lymphoblastic Leukemia research
- Acute Ischemic Stroke Management
- Blood Pressure and Hypertension Studies
- Urinary Bladder and Prostate Research
- Pharmaceutical industry and healthcare
- Urological Disorders and Treatments
- Case Reports on Hematomas
- Chronic Myeloid Leukemia Treatments
- Acute Myocardial Infarction Research
- Urologic and reproductive health conditions
- Hematopoietic Stem Cell Transplantation
University of Michigan
2019-2024
Michigan Medicine
2020-2024
Michigan United
2024
Children's Hospital of Michigan
2007
It is unclear how many patients treated with a direct oral anticoagulant (DOAC) are using concomitant acetylsalicylic acid (ASA, or aspirin) and this affects clinical outcomes.To evaluate the frequency outcomes of prescription ASA DOAC therapy for atrial fibrillation (AF) venous thromboembolic disease (VTE).This registry-based cohort study took place at 4 anticoagulation clinics in Michigan from January 2015 to December 2019. Eligible participants were adults undergoing treatment AF VTE,...
For patients anticoagulated with direct oral anticoagulants (DOACs) or warfarin and on aspirin (ASA) for nonvalvular atrial fibrillation and/or venous thromboembolism, it is unclear if bleeding outcomes differ.
Background While direct oral anticoagulants (DOACs) may be viewed as simpler to manage then warfarin, they present their own unique management challenges resulting in frequent off-label dosing. It is unknown what extent dosing occurs when a patient started on DOAC versus later treatment. Objectives We aimed better characterize occurring and evaluate the effectiveness of prescribing oversight using registry-based intervention. Methods evaluated data from Michigan Anticoagulation Quality...
Abstract To evaluate the outcome of children with high hyperdiploid acute lymphoblastic leukemia (hHDALL) treated at author's institution. One hundred thirty‐five consecutive B‐precursor ALL were diagnosed between 1991 and 2002: 38 (28.1%) hHDALL 97 (71.9%) non‐hHDALL. In group, 11/38 (28.9%) relapsed a median interval 2.8 years (range: 0.8–5.0 years) 9/11 relapses occurring end or after completion therapy. Three (27.3%) isolated hematopoietic (BM), while eight (72.7%) either extramedullary...
This cohort study evaluates stroke and major bleeding rates before after switching from warfarin to a direct oral anticoagulant (DOAC) in patients grouped by pre-switch time-in-therapeutic range guideline thresholds.